Bayesian Capital Management’s Karuna Therapeutics, Inc. Common Stock KRTX Stock Holding History

Bayesian Capital Management’s Portfolio KRTX Stock Details KRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-1,346	Closed	-$292K	–	1080
2023 Q2	$292K	Buy	+1,346	New	+$288K	0.03%	548
2022 Q4	–	Sell	-7,469	Closed	-$1.68M	–	1089
2022 Q3	$1.68M	Buy	7,469 +5,600	+300%	+$1.13M	0.34%	65
2022 Q2	$236K	Buy	+1,869	New	+$215K	0.04%	568

Other funds holding KRTX

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Sofinnova Investments Menlo Park, California $2.63B AUM 117.41% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

General Atlantic New York $2.15B AUM 35.02% 1-Year Est. Return

Bayesian Capital Management's KRTX Position: Q3 2023 in Review

Bayesian Capital Management sold out of Karuna Therapeutics, Inc. Common Stock (KRTX) in Q3 2023, closing a stake of 1,346 shares — an estimated $292K sold.

Bayesian Capital Management first reported a position in KRTX in Q2 2022 and held it in 3 quarters. The position peaked at $1.68M in Q3 2022. 256 funds tracked by Wall St. Rank hold KRTX as of Q3 2023.

Bayesian Capital Management reported no remaining Karuna Therapeutics, Inc. Common Stock position as of Q3 2023 after selling out during the quarter.
Bayesian Capital Management sold 1,346 Karuna Therapeutics, Inc. Common Stock shares in Q3 2023, an estimated $292K.
Bayesian Capital Management first reported a position in Karuna Therapeutics, Inc. Common Stock in Q2 2022 and held it in 3 quarters.
Bayesian Capital Management's Karuna Therapeutics, Inc. Common Stock position peaked at $1.68M in Q3 2022.
256 funds tracked by Wall St. Rank held Karuna Therapeutics, Inc. Common Stock as of Q3 2023.

Based on Bayesian Capital Management's 13F filing for Q3 2023, filed 14 Nov 2023.